Warning over graphene investment scams


The UK Financial Conduct Authority (FCA) has warned investors to beware of scams involving graphene, as evidence of a graphene investment company was found on a computer belonging to a suspected ‘boiler room’ company.

Graphene, the two-dimensional allotrope of carbon, has drawn increasing media attention in recent years, often dubbed a ‘wonder material’ with many potential uses, from next-generation batteries to flexible electronics. The FCA warns that scammers may be using this to their advantage, selling bogus investments in graphene over the phone. Often, it said, investors do not realise graphene is still many years away from being used in consumer products.

The regulator warned investors not to be fooled by the hype surrounding graphene. ‘There is a strong possibility of fraud with graphene because it is unregulated and it is difficult to confirm that you have bought the genuine product,’ it told consumers. ‘If it sounds too good to be true, it probably is!’


Related Content

UK failing to capitalise on graphene

1 November 2013 News and Analysis

news image

Graphene may have been discovered in the UK, but report warns that country's industry is falling behind global competitors

Nobel laureates warn on European science funding cuts

25 February 2015 News and Analysis

news image

Cuts to fund investment scheme send message Europe 'is not the place to do high level science'

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Chemists zinc up ‘aromatic’ metal cubes

2 March 2015 Research

news image

Metal-organic clusters share electrons between eight covalently linked metal atoms

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent